State of Louisiana
Office of Alcohol and Tobacco Control

Jeff Landry
GOVERNOR

Jarrod Coniglio
SECRETARY

CHAD M. BROWN
ATC COMMISSIONER

ATC PUBLIC ADVISORY: 2026-003

Publication Date: November 13, 2026

Confirmed Test Results (KLAZ) and Additional Schedule I Kratom-Related Substances

Supplement to ATC Public Advisory No. 2026-002 issued September 25, 2026

All ATC Permit Holders, Retailers, and Wholesalers,

The purpose of this supplement updates Public Advisory No. 2026-002 with completed laboratory results and recent changes to state and federal law. Advisory No. 2026-002 remains in effect, as supplemented. All products identified in that advisory have now been confirmed to contain Schedule I controlled dangerous substances under Louisiana law.

What Has Changed

- **Testing complete.** Laboratory testing of **Klaz,** which was pending when Advisory No. 2026-002 was issued, has confirmed the presence of mitragynine and/or MGM-15 (dihydro-7-hydroxymitragynine).
- **New Louisiana Schedule I substances.** By emergency rule effective September 18, 2026[1] (LAC 46:LIII.2704), the Louisiana Department of Health ("LDH") placed mitragynine pseudoindoxyl ("MGPI"), MGM-15 (dihydro-7-hydroxymitragynine), and MGM-16 (9-fluoro-dihydro-7-hydroxymitragynine) in Schedule I of the Uniform Controlled Substance Act. The rule covers their isomers, esters, ethers, and salts, and any material, compound, mixture, or preparation containing any quantity of these substances.
- **Federal update.** The DEA's temporary order placing these three substances in federal Schedule I (91 FR 54948, Aug. 26, 2026) remains in effect.

Confirmed Product Results

Product	Confirmed Substance(s)	Louisiana Authority
Buzzers	Mitragynine and/or 7-hydroxymitragynine (7-OH)	Act 41 of 2025; R.S. 40:964, Schedule I
Better Weather	7-OH; mitragynine pseudoindoxyl (MGPI)	Act 41 of 2025; LAC 46:LIII.2704 (LDH Emergency Rule)
Brighter Skies	7-OH; mitragynine pseudoindoxyl (MGPI)	Act 41 of 2025; LAC 46:LIII.2704 (LDH Emergency Rule)
Klaz	Mitragynine and/or MGM-15 (dihydro-7-hydroxymitragynine).	Act 41 of 2025; LAC 46:LIII.2704 (LDH Emergency Rule)

[1] https://www.doa.la.gov/doa/osr/emergency-rules/

Results confirmed by forensic laboratory analysis. Products identified in this advisory may be marketed as herbal supplements, botanicals, or "Cat's Claw." A product's label or marketing does not determine its legal status; the content of the products does.

Legal Consequences

Permit holders may not possess, permit on or about the licensed premises, sell, or offer for sale any controlled dangerous substance, including the substances listed above. Violations may result in administrative action against the permit, including fines, suspension, or revocation, under Title 26 of the Louisiana Revised Statutes and Title 55 of the Louisiana Administrative Code. Possession and distribution of these substances are also criminal offenses under the Uniform Controlled Dangerous Substances Law, R.S. 40:961 et seq.

Required Action — Effective Immediately

1. Remove from the licensed premises all products listed above and any other product containing kratom or kratom-related compounds, regardless of brand name or labeling.
2. **Voluntary surrender.** Permit holders may voluntarily surrender these products to ATC by contacting ATC-Complaints@atc.la.gov. ATC will not pursue administrative action against a permit holder for possession of products voluntarily surrendered before the products are discovered by ATC once an inspection or investigation commences. Products discovered by ATC will be seized as evidence and are subject to all penalties allowed by law. Voluntary surrender does not limit the authority of any other agency.
3. Remove all signs, displays, and advertising that reference the offer for sale of kratom or kratom-related products, as directed in ATC Advisory No. 2026-004 (Compliance).
4. Review inventory and supplier invoices for products marketed as herbal or botanical supplements with similar effects or packaging.
5. Inform all employees and managers of this supplement.

Consumer Alert: These products are potent opioid-like substances that carry risks including dependence and respiratory depression. Anyone experiencing an adverse reaction should seek medical attention immediately.

Compliance Reminder: Permit holders are responsible for all violations occurring on or about the licensed premises. Permit holders are encouraged to consult legal counsel regarding their compliance obligations.

Sincerely,

Chad M. Brown
Commissioner
Office of Alcohol and Tobacco Control